#1292ef

Fresenius Kabi

#f9f9f9

Stephan Sturm

Michael Sen

Sebastian Biedenkopf

Francesco De Meo

Rachel Empey

Rice Powell

Ernst Wastler

Stefanie Metzner

Nina Kosovel Malekovic

Isaac Lai

Iris Maag-zahner

Suhas Jeurkar

Rezzan Ozogul Newton

Joao Carlos Serra

Marius Van Der Tuijn

Regis Berthier

Jarkko Ala-heikkila

Pieter Bories

Victor Manuel Caldera Chocano

Usama Eldahshan

Julie Van Der Auwera

Laura-jane Marris

Michaela Ries

Helmut M. Becker

Janice Tan

Sonja Zemelka

Kirsten Christiani

Matthias Tyssen

Emeric Mermet

Catharina M. Daevel

Nikhil Koli

Nina Brechan

Tom Burton

Niels E. Hower

Guangyu Wang

Stefanie Schum

Ahmad Rizal

Anna Petzen

Pedro Coelho

Tim Hanisch

Peter Friderichs

Jana C

Hilary Metcalfe

Sunil Honkalas

Dolores Juarez

Marc-antoine Dang

Thuy Van Nguyen

Cyril Deleaval

Aaron Kwok

Ekaterina Latysheva

Jessica Chan

Darius Panaligan

Wim Hermans

Jan Painter

Mohamed Askar

Stephan Stoiser

Marcin Iwanczuk

Helmut Knoller

Heike Van Dawen

Andrea Nicholson

Arnaud Meurant

Sylwia Malinowska

Stefanie Wach

Michael Gab

Katja Baumeister

Alicia Martin

Solene Darmon

Stefan Blei

Christian Schafer

Michelle Vankenhove

Laurent Rebier

Roel Beerling

Sarah Tohill

Timothee De Chevron Villette

Christian Ruth

Manas Sahoo

Didier Leyman

Stefan Vogt

Lars Michel

Barbara Amon

Feng Liu

Ashis Patnaik

#87c5f2

Corporate Leadership

Human Resources

CEO Fresenius Helios

Finance

Fresenius Medical Care

CEO Fresenius Vamed

Marketing

Sales & Marketing

Enteral Nutrition Marketing

Strategic Marketing

Clinical Nutrition Marketing

Other Marketing

Procurement

Procurement Enternal nutrition

Sourcing

Research & Development

Fresenius Kabi is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific. Within I.V. generic drugs, Fresenius Kabi ... 

We use cookies to ensure the correct functioning of this website, provide the best possible service to you, enhance your user experience, and optimize our website. Find out more about how we use cookies  and  how you can change your settings .
I consent Refuse Cookies
Home
Fresenius Kabi
Our commitment goes beyond treating the disease so patients can move forward
Our commitment goes beyond treating the disease so patients can move forward
Our commitment goes beyond treating the disease so patients can move forward
A commitment to high-quality biosimilar development
A commitment to high-quality biosimilar development
A commitment to high-quality biosimilar development
Living with a chronic disease: A patient?s testimony
read more
Living with a chronic disease: A patient?s testimony
read more
Living with a chronic disease: A patient?s testimony
read more
Living with Rheumatoid Arthritis: Patient Testimony
read more
Living with Rheumatoid Arthritis: Patient Testimony
read more
Living with Rheumatoid Arthritis: Patient Testimony
read more
Providing access to affordable medicines to those in need
read more
Providing access to affordable medicines to those in need
read more
Providing access to affordable medicines to those in need
read more
Our commitment goes beyond treating the disease so patients can move forward
Our commitment goes beyond treating the disease so patients can move forward
A commitment to high-quality biosimilar development
A commitment to high-quality biosimilar development
Living with a chronic disease: A patient?s testimony
read more
Living with a chronic disease: A patient?s testimony
read more
Living with Rheumatoid Arthritis: Patient Testimony
read more
Living with Rheumatoid Arthritis: Patient Testimony
read more
Providing access to affordable medicines to those in need
read more
Providing access to affordable medicines to those in need
read more
News
February 16, 2023
Fresenius Kabi launches biosimilar Stimufend? (pegfilgrastim-fpgk) in the U.S.
read more
February 2, 2023
Fresenius Kabi announces global license agreement with Formycon AG to commercialize proposed Ustekinumab biosimilar
read more
December 14, 2022
Fresenius Kabi receives U.S. FDA approval for biosimilar Idacio? (adalimumab)
read more
September 6, 2022
Fresenius Kabi receives U.S. FDA approval for biosimilar Stimufend? (pegfilgrastim)
read more
August 18, 2022
Fresenius Kabi announces Acceptance of its Marketing Authorization Application by the European Medicines Agency for MSB11456, a Tocilizumab Biosimilar Candidate
read more
August 10, 2022
Fresenius Kabi establishes partnership with Bio-Manguinhos/Fiocruz and Bionovis to provide access to adalimumab biosimilar in Brazil
read more
August 2, 2022
Fresenius Kabi?s Biologics License Application for Biosimilar Candidate Tocilizumab Accepted for Review by the FDA
read more
August 1, 2022
Fresenius Kabi completes majority stake acquisition of mAbxience Holding S.L., significantly enhancing presence in high-growth biopharmaceuticals market
read more
July 27, 2022
A biosimilar patient story: "I can live my life again and not feel fear"
read more
May 23, 2022
EuroPN Study: New clinical data on medical nutrition therapy in critically ill patients
read more
February 16, 2023
Fresenius Kabi launches biosimilar Stimufend? (pegfilgrastim-fpgk) in the U.S.
read more
February 2, 2023
Fresenius Kabi announces global license agreement with Formycon AG to commercialize proposed Ustekinumab biosimilar
read more
December 14, 2022
Fresenius Kabi receives U.S. FDA approval for biosimilar Idacio? (adalimumab)
read more
September 6, 2022
Fresenius Kabi receives U.S. FDA approval for biosimilar Stimufend? (pegfilgrastim)
read more
August 18, 2022
Fresenius Kabi announces Acceptance of its Marketing Authorization Application by the European Medicines Agency for MSB11456, a Tocilizumab Biosimilar Candidate
read more
August 10, 2022
Fresenius Kabi establishes partnership with Bio-Manguinhos/Fiocruz and Bionovis to provide access to adalimumab biosimilar in Brazil
read more
August 2, 2022
Fresenius Kabi?s Biologics License Application for Biosimilar Candidate Tocilizumab Accepted for Review by the FDA
read more
August 1, 2022
Fresenius Kabi completes majority stake acquisition of mAbxience Holding S.L., significantly enhancing presence in high-growth biopharmaceuticals market
read more
July 27, 2022
A biosimilar patient story: "I can live my life again and not feel fear"
read more
May 23, 2022
EuroPN Study: New clinical data on medical nutrition therapy in critically ill patients
read more
Our commitment to patients
See how we are going beyond what?s expected for our patients
read more
Our Expertise
Learn more on our long-standing heritage as a trusted partner helping us put patients first
read more
Our biosimilars
Discover more about our biosimilar know how
read more
Our commitment to patients
See how we are going beyond what?s expected for our patients
read more
Our Expertise
Learn more on our long-standing heritage as a trusted partner helping us put patients first
read more
Our biosimilars
Discover more about our biosimilar know how
read more
Congresses
Fresenius Kabi SwissBioSim GmbH ? December 2023
Go to top
https://www.fresenius-kabi.com/binding-corporate-rules-bc

Being member of various industry associations, we have committed ourselves to disclose certain value transfers to HCPs, HCOs and patient care organizations